Hyperbaric oxygen therapy restores blood supply and promotes healing in medication-related osteonecrosis of the jaw
Hyperbaric oxygen therapy restores blood supply and promotes healing in medication-related osteonecrosis of the jaw
Understanding MRONJ and how HBOT addresses its avascular jaw bone pathology
Medication-Related Osteonecrosis of the Jaw (MRONJ) is a serious and increasingly common complication of bisphosphonate therapy (Fosamax, Zometa, Aredia, Boniva, Actonel) and anti-RANKL therapy (denosumab — Prolia, Xgeva). These drugs are widely used to treat osteoporosis, bone metastases from breast, prostate and lung cancers, multiple myeloma and other conditions where bone loss or pathological fractures are a concern.
Bisphosphonates and denosumab both suppress osteoclast activity — the bone cells responsible for resorbing and remodeling bone tissue. While this suppression is therapeutically useful for reducing pathological bone loss, it also impairs the jaw bone’s ability to remodel and repair after minor trauma such as tooth extraction, dental implant placement or even spontaneous gum injury. The jaw is uniquely vulnerable because it is subject to constant mechanical stress, dental procedures and exposure to oral bacteria, all of which create small tissue injuries that require active bone remodeling to heal.
MRONJ is defined as exposed, necrotic bone in the jaw that has been present for more than 8 weeks in a patient taking or previously exposed to bisphosphonate or denosumab therapy, without a history of radiation therapy to the jaw (which distinguishes it from osteoradionecrosis). It presents in three stages: Stage 1 (asymptomatic exposed bone), Stage 2 (exposed bone with pain and infection), and Stage 3 (exposed bone with complications including pathological fracture, fistula or extension to the inferior border of the mandible).
The pathophysiology of MRONJ parallels osteoradionecrosis: the jaw bone becomes avascular (lacking adequate blood supply), hypoxic (oxygen-deprived) and hypocellular (unable to support normal bone remodeling). HBOT addresses these three deficiencies directly — the same mechanisms that make HBOT effective in osteoradionecrosis (which is a Medicare-approved HBOT indication) operate identically in MRONJ.
Exposed bone visible in the mouth, typically after a dental procedure or spontaneously
Jaw pain, swelling and redness around the exposed bone area
Difficulty eating, chewing and opening the mouth
Numbness or heaviness of the jaw (numb chin syndrome from inferior alveolar nerve involvement)
Fistula (abnormal opening) from the bone to the skin or mouth in advanced cases
Pathological fracture of the jaw in severe Stage 3 disease
How HBOT addresses the avascular, hypoxic bone pathology of MRONJ
MRONJ shares its fundamental pathology with osteoradionecrosis: avascular, hypoxic, hypocellular bone that cannot heal. HBOT’s established effectiveness in radiation jaw necrosis directly translates to the same mechanisms in MRONJ.
Restores oxygen and blood supply to avascular jaw bone
Stimulates bone healing and remodeling
Controls infection in the necrotic bone
Reduces jaw pain and wound inflammation
Supports surgical debridement and mucosal healing
May allow dental procedures in high-risk patients
For Providers
Clinical evidence for HBOT in medication-related osteonecrosis of the jaw
Evidence for HBOT in MRONJ includes systematic reviews, controlled case series and the strong mechanistic parallel with osteoradionecrosis, where HBOT has a long-established track record and Medicare approval.
Freiberger et al. — controlled study (2012): John Freiberger and colleagues at Duke University published a controlled study comparing HBOT plus standard surgical management versus standard surgical management alone in MRONJ patients. The HBOT group demonstrated significantly better mucosal healing rates, fewer wound breakdowns, and lower rates of MRONJ recurrence at follow-up. The perioperative HBOT protocol (sessions before and after surgery) produced the best outcomes, consistent with the established approach for osteoradionecrosis. [Freiberger JJ et al. J Oral Maxillofac Surg. 2012;70(5):1219–1232. PMID: 22516762]
Mücke et al. — systematic review (2016): A systematic review of HBOT for MRONJ examined the available published evidence and concluded that HBOT is a beneficial adjunct to surgical management, with consistent improvements in wound healing, pain reduction and mucosal closure across the reviewed studies. The review noted that the perioperative protocol produces the most consistently positive outcomes and recommended HBOT as part of a multidisciplinary MRONJ management approach. [Mücke T et al. Int J Oral Maxillofac Surg. 2016;45(2):166–175. PMID: 26508278]
Osteoradionecrosis parallel — the mechanistic foundation: HBOT’s effectiveness in osteoradionecrosis is well-established and Medicare-approved, resting on the Marx mechanism: hyperbaric oxygen stimulates angiogenesis in avascular bone, progressing the bone from a hypoxic-hypovascular-hypocellular state to a normoxic-normovascular-normocellular state that can support healing. MRONJ creates identical jaw bone pathology through a different mechanism (suppressed osteoclast remodeling rather than radiation endarteriitis), but the same HBOT mechanisms address it. This parallel is the primary rationale for HBOT in MRONJ. [Marx RE. J Oral Maxillofac Surg. 1983;41(5):283–286. PMID: 6572776]
Anaerobic infection control: MRONJ necrotic bone is invariably colonized by anaerobic bacteria including Actinomyces, Fusobacterium and other oral anaerobes that thrive in the avascular, hypoxic bone environment. HBOT at 2.0 to 2.4 ATA creates tissue oxygen tensions directly bactericidal for these anaerobes, reduces biofilm resilience and restores neutrophil oxidative killing in infected bone tissue — addressing the infectious component that perpetuates bone destruction.
Our MRONJ HBOT protocol at Bay Area Hyperbarics
HBOT for MRONJ is most effective when integrated with surgical management — the perioperative protocol of pre- and post-operative HBOT in conjunction with surgical debridement has the strongest evidence base. HBOT alone without adequate surgical management is less effective in advanced MRONJ. We work closely with your oral surgical team to coordinate the combined approach.
Oral surgery, oncology and dental coordination
Our medical team reviews your medication history (bisphosphonate type, dose, duration, route; or denosumab use), MRONJ stage, jaw imaging (panoramic X-ray, CT), current symptoms and prior treatments. We coordinate with your oral surgeon, oncologist and dentist to integrate HBOT into a comprehensive MRONJ management plan covering staging, surgical planning and long-term follow-up.
Perioperative HBOT protocol — before and after surgery
The most evidence-supported HBOT protocol for MRONJ follows the Marx perioperative model: 20 sessions of HBOT before surgical debridement, followed by 10 sessions after surgery. This protocol is designed to optimize jaw bone vascularity and oxygenation before surgery and support mucosal healing and bone repair after it. For non-surgical management, longer continuous courses of 30 to 40 sessions are used.
Long-term monitoring and recurrence prevention
MRONJ has a significant recurrence risk, particularly in patients who continue or resume bisphosphonate or denosumab therapy. We coordinate long-term follow-up with your oral surgeon and oncologist, and discuss the role of maintenance HBOT in patients at high recurrence risk — including those who cannot discontinue their bone-protective medications due to cancer-related indications.
Frequently Asked Questions
Answers to the questions MRONJ patients and their healthcare providers most often ask about HBOT.
Osteoradionecrosis (ORN) and MRONJ share the same core pathology: avascular, hypoxic, hypocellular jaw bone that cannot heal. In ORN, radiation obliterates the jaw’s blood vessels. In MRONJ, bisphosphonates and denosumab suppress the bone remodeling and angiogenesis needed to maintain jaw vascularity. Both create bone with insufficient blood supply and oxygen to support healing. HBOT addresses this shared pathology through the same mechanisms: stimulating angiogenesis, restoring osteoblast function and controlling anaerobic infection. ORN is a Medicare-approved HBOT indication — the parallel with MRONJ is the primary mechanistic basis for HBOT in MRONJ.
Dealing with jaw necrosis from bisphosphonates or denosumab? Ask us about HBOT
Bay Area Hyperbarics provides HBOT for MRONJ as an adjunct to dental and surgical management. Our team coordinates with your oral surgeon, oncologist and dentist to integrate HBOT into your treatment plan. Call us to discuss your situation and whether HBOT can help.
